Examining medicine shortages and their consequences through economic, clinical, and economic lens
A study on medicine shortages in the Netherlands found that disease and costs were the two most affected elements, with 30% and 20% of shortages rated high on these elements, respectively. The study used a framework of economic, clinical, and patient outcomes to assess the impact of medicine shortages on patients. Direct impact, represented by alternative product and disease, was rated high for 30% of the shortages, while indirect impact, represented by costs, susceptibility, and number of patients, was rated high for 17% of the shortages. No significant differences in impact scores were found based on product characteristics.
Recent Posts
Multistakeholder Approaches to Optimize Oncology Market Access Strategy
Effective oncology market access strategy has become markedly more complex as geopolitical pressures reshape how innovative cancer therapies reach patients, as made clear in Iroda Jurabekova’s pharma summit presentation. Determining whethe...
Advancing Real-World Evidence AI in Medicines Regulation
The adoption of Real-World Evidence AI is reshaping how the European Medicines Agency evaluates medicines, according to the European Medicines Agency’s annual report. By moving these technologies from pilot project...
Strengthening Medicine Shortages Management for Enhanced Availability and Access
The European Medicines Agency made medicine shortages management a foundational policy objective in 2025, as highlighted in its annual reports and work programmes. By advancing coordinated shortages oversight and d...